Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Nov;14(22):1555-63.
doi: 10.1038/sj.gt.3303033.

Progress and prospects: gene therapy clinical trials (part 2)

A Aiuti, A C Bachoud-Lévi, A Blesch, M K Brenner, F Cattaneo, E A Chiocca, G Gao, K A High, A M Leen, N R Lemoine, I A McNeish, G Meneguzzi, M Peschanski, M G Roncarolo, D S Strayer, M H Tuszynski, D J Waxman, J M Wilson
Review

Progress and prospects: gene therapy clinical trials (part 2)

A Aiuti et al. Gene Ther. 2007 Nov.

Erratum in

  • Gene Ther. 2007 Dec;14(24):1754. Alton, Eric [removed]; Ferrari, Stefano [removed]; Griesenbach, Uta [removed]; Aiuti, A [added]; Bachoud-Lévi, A C [added]; Blesch, A [added]; Brenner, M K [added]; Cattaneo, F [added]; Chiocca, E A [added]; Gao, G [added]; High, K A [added]; Leen, A M [a

Abstract

This is the second part of a review summarizing progress and prospects in gene therapy clinical research. Twenty key diseases/strategies are succinctly described and commented on by leaders in the field. This part includes clinical trials for skin diseases, neurological disorders, HIV/AIDS, ornithine transcarbamylase deficiency, alpha(1)-antitrypsin deficiency, haemophilia and cancer.

PubMed Disclaimer

MeSH terms